Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Myeloid Malignancies

Christophe Ferrand  1 , Alessandro Rambaldi  2
Nicolaus Kröger  1 , John Gribben  2 , Christian Chabannon  3 , Ibrahim Yakoub-Agha  4 , Hermann Einsele  5
, editors.
In: The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 18.
.
Affiliations
Free Books & Documents
Review

Myeloid Malignancies

Christophe Ferrand et al.
Free Books & Documents

Excerpt

In addition to chemotherapy, which remains the basic treatment, the treatment panel for acute myeloid leukaemia (AML) has expanded considerably in recent years. Clinicians now have a large choice of therapies: targeted therapies (anti-IDH1/2, anti-FLT3, and anti-BCL2 therapies, among others), drugs targeting epigenetic mechanisms, kinase inhibitors (FLT3, MAPK, and JAK2, etc.), immunotherapies (monoclonal antibodies linked or not to a toxin, dual/bispecific), and cellular immunotherapies. Moreover, despite its toxicities, allogeneic transplantation often remains an effective final therapeutic alternative. However, most patients are refractory or relapsed (R/R) after several lines of therapy. Thus, there is a clinical need in AML R/R patients, and CAR-T cells may be an option and can find a place in the treatment to reduce tumour burden and clinical evolution of the disease (Fig. 18.1, modified from Roussel et al. (2020)).

PubMed Disclaimer

References

    1. Anonymous. Augmenting CAR-T cells with PD-1 blockade. Cancer Discov. 2019;9(2): 158. https://doi.org/10.1158/2159-8290.CD-NB2018-165. - DOI - PubMed
    1. Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 2017;25(8):1933–45. https://doi.org/10.1016/j.ymthe.2017.04.017. - DOI - PMC - PubMed
    1. Borrega G, Jorge PG, Rüger MA, Onur ÖA, Shimabukuro-Vornhagen A, Kochanek M, Böll B. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. HemaSphere. 2019;3(2):e191. https://doi.org/10.1097/HS9.0000000000000191. - DOI - PMC - PubMed
    1. Casucci M, di Robilant BN, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122(20):3461–72. https://doi.org/10.1182/blood-2013-04-493361. - DOI - PubMed
    1. Cummins KD, Gill S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? Haematologica. 2019;104(7):1302–8. https://doi.org/10.3324/haematol.2018.208751. - DOI - PMC - PubMed

LinkOut - more resources